Stay tuned for full program.
Thursday, July 14
Arrival and Registration
Aerial gondola tour and mountain hike for early arrivers
Welcome reception (wine and hors d'oeuvres)
Friday, July 15
Welcome from the organizers
- General overview of nanomedicine: Skepticism or optimism?
Morning session 1: Immunological and cellular barriers, protein corona and toxicity
Chair: Thomas Anchordoquy
- Nanosafety: No small issue (M. Moghimi, Durham University, UK)
- Complement and immune uptake of nanomedicines: How to avoid unavoidable? (D. Simberg, University of Colorado Denver)
- Macrophage reprogramming with nanoparticles: Modulating, etc. (D. Boraschi, Research Council of Italy)
- Nanoparticle-based MRI on tumor associated macrophages: Promises and challenges in imaging inflammation (Natalie Serkova, University of Colorado)
Morning session 2: Tumor barriers and targets
Chair: P. Decuzzi
- Keynote: Tumor-penetrating peptides in nanoparticle targeting (E. Ruoslahti, Sanford-Burnham-Prebys)
- Where the wild things are: Perivascular regulation of tumor cell dormancy and drug resistance (C. Ghajar, Fred Hutchinson Cancer Center)
- Immunotherapeutics targeting the tumor microenvironment: Opportunities for nanomedicine (Stephen Dow, Colorado State University)
- Nanobioconjugates delivered through multiple biobarriers regulate laminin-411 -- Notch signaling pathways to fight cancer (Julia Ljubimova, Cedars-Sinai Hospital)
Afternoon session: Engineering aspects in nano drug delivery
Chair: Dan Peer
- The 4S parameters in the rational design of nanomedicines (P. Decuzzi, Italian Institute of Technology)
- Hyperthermia approaches for enhanced delivery of polymer therapeutics (H. Ghandehari, University of Utah)
- Overcoming barriers for nanoparticle delivery using circulatory cells (S. Mitragotri, University of California Santa Barbara)
Coffee break and light snacks
Free time; Dinner on your own
Saturday, July 16
Morning session 1: Barriers to translation
Chair: Gabriel Lopez-Bernstein
- Keynote: Improving nano-drugs' therapeutic efficacy through their interaction with tumor microenvironment (Y. Barenholz, Hebrew University of Jerusalem)
- Optimizing nanoparticle delivery of chemotherapeutics - The clinical challenge (A. Gabizon, Hebrew University of Jerusalem)
- Impact of nanoparticles on the tumor immunologic milieu: Promise and peril (I. La Beck, Texas Tech)
- Preclinical immunotoxicity studies of nanotechnology-formulated drugs: Lessons learned, challenges and strategy (M. Dobrovolskaia, Nanotechnology Characterization Lab, NIH)
Morning session 2: Barriers to translation 1: Manufacturing and regulatory/funding hurdles
Chair: Shadi Farhangrazi
- Biologics and peptides by a new encapsulation process: High-loading, high-encapsulation efficiency, and protected delivery as nanoparticles or depots (R. Prudhomme, Princeton University)
- Translation of a cancer nanotherapeutic into the clinic: A view from the trenches (L. Pagliaro, Siva Therapeutics)
- NIH/NCI Perspective on nanomedicine climate (D. Farrell)
Afternoon session: Organ/tissue/cell-specific barriers and special topics
Chair: Dmitri Simberg
- Biophysical barriers in respiratory drug delivery (H. Smyth, UT Austin)
- To target or not to target: Lessons from RNAi-based targeted lipid-based nanoparticles to solid tumors and leukocytes (D. Peer, University of Tel Aviv)
- Exploiting cells in the tumor microenvironment for nanovector based therapy (B. Godin, Methodist Hospital)
- Extracellular vesicles-mediated penetration of therapeutic compounds in solid tumors (JH Park, Kaist, S. Korea)
Registration fee includes coffee breaks, reception, farewell dinner, and all meals, with the exception of dinner on July 15.
*Student early bird deadline extended to June 30, 2016.
**Meals for accompanying family members to be announced.
- Before May 1, 2016: Full Refund minus $30 processing fee
- May 1-June 15, 2016: 50% Refund
- After June 15, 2016: No Refund
The organizers are offering reduced rates to students and postdocs. Hotel rooms are limited in July, so register early! Room reservation is separate from the conference reservation. After completing the registration, please vist the Travel and Accommodation tab for information on hotel reservations.
The workshop will be held at the Beaver Run Resort and Conference Center in Breckenridge, Colorado – a beautiful
ski resort town in the Rocky Mountains.
Beaver Run Resort and Conference Center
is a full-service property featuring over 500 unique lodging units
(individually owned and decorated, from single rooms to family suites). It is
the largest conference center in Breckenridge and offers a variety of resort
amenities including a swimming pool and spas.
A block of rooms for the workshop has been reserved at a discounted rate.
If you need a
special accommodation (condo, family, disability, etc.), please call
(800) 525-2253 and reference the "Mechanisms and Barriers in Nanomedicine
Conference" to receive the group rate. The rate for a basic hotel room, which can accommodate two people, is $135 (excluding taxes).
Typical driving distance from the Denver
International Airport (DIA) to Breckenridge, Colorado, is about 1 hour and 45 minutes. There are many shuttle services offering routes from DIA to Breckenridge ranging in rates from $45-$65. Here are a few:
Organizers will reserve a disounted rate for the shuttle returning to the airport on Sunday.
The town of Breckenridge offers a
variety of shops, historic sites, and over 150 restaurants and bars. With
average daytime temperatures in the mid-70’s and 10% humidity, it is an ideal
area for a variety of outdoor activities, including whitewater rafting,
mountain or road cycling, jeep and ATV tours, zip line adventures, climbing 14ers
or horseback riding. For a more relaxing day, there is a golf course, fly
fishing, or hiking.
Thomas Anchordoquy, University of Colorado, US
Chezy Barenholz, The Hebrew University of Jerusalem, Israel
Diana Boraschi, National Research Council, Italy
Paolo Decuzzi, Italian Institute of Technology in Genoa, Italy
Marina Dobrovolskaia, Nanotechnology Characterization Laboratory, US
Stephen Dow, Colorado State University, US
Shadi Farhangrazi, Biotrends International and University of Denver, US
Dorothy Farrell, National Cancer Institute, US
Alberto Gabizon, The Hebrew University of Jerusalem, Israel
Cyrus Ghajar, Fred Hutchinson Cancer Research Center, US
Hamid Ghandehari, University of Utah, US
Irene La-Beck, Texas Tech University, US
Julia Ljubimova, Cedars-Sinai Hospital, US
Gabriel Lopez-Berestein, MD Anderson Cancer Center, US
Samir Mitragotri, University of California, Santa Barbara, US
Moien Moghimi, Durham University, UK
Len Pagliaro, Siva Therapeutics, US
Ji Ho Park, Kaist, South Korea
Dan Peer, University of Tel Aviv, Israel
Robert Prud'homme, Princeton University, US
Erkki Ruoslahti, Prebys-Sanford-Burnham, US
Natalie Serkova, University of Colorado, US
Dmitri Simberg, University of Colorado, US
Hugh Smyth, University of Texas at Austin, US
Biana Godin Vilentchouk, Methodist Hospital, US